English

THERAPEUTIC ANTIBODIES INC /DE

EDGAR

Quarterly report (10-Q) · filed 1999-08-13

17 filing records in this dataset, filed from 1996-08-14 to 1999-08-13. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Insider filings have not been processed for this company yet.

See all insider transactions

Latest quarter

Revenue

9.46 million USD

1999-06-30 · USD

Exact inputs and evidence

Revenue: 9461841 USD Source

Operating margin

-831.65%

1999-06-30 · %

Exact inputs and evidence

Operating Income: -78689473 USD Source
Revenue: 9461841 USD Source

Operating cash flow

60.6 million USD

1999-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -6688199 USD Source
Operating Cash Flow: -67329207 USD Source

Cash and cash equivalents: 2.27 million USD 1999-06-30 Source
Exact value

2268914 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-14.3 million USD

1998-07-01 – 1999-06-30

Exact inputs and evidence

Operating cash flow: -10843024 USD · 1998-01-01 – 1998-09-30 Source
Operating cash flow: -56765127 USD · 1998-01-01 – 1998-06-30 Source
Operating cash flow: -64359721 USD · 1998-01-01 – 1998-12-31 Source
Operating cash flow: -10843024 USD · 1998-01-01 – 1998-09-30 Source
Operating cash flow: -67329207 USD · 1999-01-01 – 1999-03-31 Source
Operating cash flow: -6688199 USD · 1999-01-01 – 1999-06-30 Source
Operating cash flow: -67329207 USD · 1999-01-01 – 1999-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 1999-08-13.

Financial data available through: 1998-12-31.

Coverage by financial measure

Revenue: 1 of 11 periods available· newest 1998-12-31
Operating income: 1 of 11 periods available· newest 1998-12-31
Net income: 2 of 11 periods available· newest 1998-12-31
Operating cash flow: 2 of 11 periods available· newest 1998-12-31
Capital expenditure: 2 of 11 periods available· newest 1998-12-31
Total assets: 1 of 11 periods available· newest 1998-12-31
Total liabilities: 1 of 11 periods available· newest 1998-12-31
Current assets: 1 of 11 periods available· newest 1998-12-31
Current liabilities: 1 of 11 periods available· newest 1998-12-31
Cash and cash equivalents: 1 of 11 periods available· newest 1998-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 15.89 million

Prior period

−USD 59.41 million

1997-01-01 – 1997-12-31
Current period

−USD 75.3 million

1998-01-01 – 1998-12-31

Exact inputs and evidence

-75301311 − -59412383 = -15888928 USD

-59412383 USD · 1997-01-01 – 1997-12-31
Inspect prior input Prior source
-75301311 USD · 1998-01-01 – 1998-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Year-over-year change in Net income: -15888928 USD Concept: fundies:NetIncome Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -75301311 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1619 Input fundies:NetIncome: -59412383 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2437
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 13.28 million

Prior period

−USD 51.08 million

1997-01-01 – 1997-12-31
Current period

−USD 64.36 million

1998-01-01 – 1998-12-31

Exact inputs and evidence

-64359721 − -51076928 = -13282793 USD

-51076928 USD · 1997-01-01 – 1997-12-31
Inspect prior input Prior source
-64359721 USD · 1998-01-01 – 1998-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Year-over-year change in Operating cash flow: -13282793 USD Concept: fundies:OperatingCashFlow Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -64359721 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1639 Input fundies:OperatingCashFlow: -51076928 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2456
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+10%

Prior period

USD 13.89 million

1997-01-01 – 1997-12-31
Current period

USD 15.27 million

1998-01-01 – 1998-12-31

Exact inputs and evidence

15273350 − 13888323 = 1385027 USD

13888323 USD · 1997-01-01 – 1997-12-31
Inspect prior input Prior source
15273350 USD · 1998-01-01 – 1998-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Year-over-year change in Capital expenditure: 1385027 USD Concept: fundies:CapitalExpenditure Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 15273350 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1643 Input fundies:CapitalExpenditure: 13888323 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2461
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

1998 1998-01-01 – 1998-12-31

Revenue USD 9.07 million 100% of revenue
Operating costs Derived USD 81.33 million 897% of revenue
Operating income −USD 72.26 million −797% of revenue
Tax, interest and other Derived USD 3.04 million 34% of revenue
Net income −USD 75.3 million −830% of revenue

Cash

Operating cash flow −USD 64.36 million −710% of revenue
Capital expenditure USD 15.27 million 168% of revenue
Free cash flow Derived −USD 79.63 million −878% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

1998 Operating loss: operating costs were 897% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
1998 1998-01-01 – 1998-12-31	9070522	81328315 Derived	-72257793	3043518 Derived	-75301311	-79633071 Derived	Source 1998-01-01 – 1998-12-31: 9070522 USD Inspect Revenue Open source 1998-01-01 – 1998-12-31: -72257793 USD Inspect Operating Income Open source 1998-01-01 – 1998-12-31: -75301311 USD Inspect Net Income Open source 1998-01-01 – 1998-12-31: -64359721 USD Inspect Operating Cash Flow Open source 1998-01-01 – 1998-12-31: 15273350 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 9.1M 1998

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
19981998-12-31	Revenue	9070522	Revenue: 9070522 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
19981998-12-31	Year over year	No prior comparable period	Revenue: 9070522 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -796.6% 1998

Net margin -830.2% 1998

Free cash flow margin -877.9% 1998

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
19981998-12-31	Operating margin	-796.6%	Operating Income: -72257793 Open source Revenue: 9070522 Open source
19981998-12-31	Net margin	-830.2%	Net Income: -75301311 Open source Revenue: 9070522 Open source
19981998-12-31	Free cash flow margin	-877.9%	Revenue: 9070522 Open source Operating Cash Flow: -64359721 Open source Capital Expenditure: 15273350 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -64.4M 1998

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
19981998-12-31	Operating cash flow	-64359721	Operating Cash Flow: -64359721 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -79.6M 1998

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
19981998-12-31	Free cash flow	-79633071	Operating Cash Flow: -64359721 Open source Capital Expenditure: 15273350 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

43.9% 1998

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
19981998-12-31	Liabilities / assets	43.9%	Total Liabilities: 9399068 Open source Total Assets: 21421502 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.37× 1998

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
19981998-12-31	Current assets / current liabilities	2.37×	Current Assets: 9574194 Open source Current Liabilities: 4037012 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
1997 1997-01-01 – 1997-12-31	−USD 59.41 million Exact value Exact value: -59412383 USD 1997-01-01 – 1997-12-31: -59412383 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAPEUTIC ANTIBODIES INC /DE · 1997-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Net Income: -59412383 USD Concept: fundies:NetIncome Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3ANetIncome&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59412383 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2437 The citation records this snapshot. The page link may show a newer release later.	−USD 51.08 million Exact value Exact value: -51076928 USD 1997-01-01 – 1997-12-31: -51076928 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAPEUTIC ANTIBODIES INC /DE · 1997-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Operating Cash Flow: -51076928 USD Concept: fundies:OperatingCashFlow Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3AOperatingCashFlow&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -51076928 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2456 The citation records this snapshot. The page link may show a newer release later.	USD 13.89 million Exact value Exact value: 13888323 USD 1997-01-01 – 1997-12-31: 13888323 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAPEUTIC ANTIBODIES INC /DE · 1997-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Capital Expenditure: 13888323 USD Concept: fundies:CapitalExpenditure Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3ACapitalExpenditure&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13888323 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2461 The citation records this snapshot. The page link may show a newer release later.	−USD 64.97 million Calculation and evidence -51076928 − 13888323 USD Exact free cash flow: -64965251 USD 1997-01-01 – 1997-12-31: -51076928 USD · Inspect Operating Cash Flow · Source 1997-01-01 – 1997-12-31: 13888323 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAPEUTIC ANTIBODIES INC /DE · 1997-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Free cash flow: -64965251 USD Concept: free-cash-flow Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -51076928 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2456 Input fundies:CapitalExpenditure: 13888323 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-98-003731.txt#2461 The citation records this snapshot. The page link may show a newer release later.
1998 1998-01-01 – 1998-12-31	−USD 75.3 million Exact value Exact value: -75301311 USD 1998-01-01 – 1998-12-31: -75301311 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Net Income: -75301311 USD Concept: fundies:NetIncome Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3ANetIncome&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75301311 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1619 The citation records this snapshot. The page link may show a newer release later.	−USD 64.36 million Exact value Exact value: -64359721 USD 1998-01-01 – 1998-12-31: -64359721 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Operating Cash Flow: -64359721 USD Concept: fundies:OperatingCashFlow Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3AOperatingCashFlow&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -64359721 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1639 The citation records this snapshot. The page link may show a newer release later.	USD 15.27 million Exact value Exact value: 15273350 USD 1998-01-01 – 1998-12-31: 15273350 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Capital Expenditure: 15273350 USD Concept: fundies:CapitalExpenditure Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744/explain?concept=fundies%3ACapitalExpenditure&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15273350 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1643 The citation records this snapshot. The page link may show a newer release later.	−USD 79.63 million Calculation and evidence -64359721 − 15273350 USD Exact free cash flow: -79633071 USD 1998-01-01 – 1998-12-31: -64359721 USD · Inspect Operating Cash Flow · Source 1998-01-01 – 1998-12-31: 15273350 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAPEUTIC ANTIBODIES INC /DE · 1998-12-31 THERAPEUTIC ANTIBODIES INC /DE (edgar:944744) Free cash flow: -79633071 USD Concept: free-cash-flow Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-14T20:13:05Z Snapshot: 46ff8b5e8ae00a5596c5abc90718a74b991fb8965e99f4bcec2fde3d8bf7fc08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/944744?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -64359721 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1639 Input fundies:CapitalExpenditure: 15273350 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/944744/0000950144-99-010186.txt#1643 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-14. Source filing dates and reporting periods are shown separately.

Identifiers: 0000944744, 944744, edgar:944744

THERAPEUTIC ANTIBODIES INC /DE

Holdings and insider activity

Latest quarter

Revenue

Operating margin

Operating cash flow

Trailing twelve months

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

1998 1998-01-01 – 1998-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation